Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
It requires a needle, which may lead to anxiety or discomfort, especially for individuals with a fear of needles
After a review of the totality of information, including all clinical data generated to date for danuglipron and recent input from regulators, Pfizer has decided to discontinue development of the molecule
Pablo de la Cueva has participated as consultant and/or investigator and/or speaker for the following pharmaceutical companies: Abbvie, Almirall, BMS, Boehringer-Ingelheim, Celgene, Janssen Cilag, LEO Pharma, Lilly, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, and UCB
Effectiveness of delivery routesinjectable versus oral/nasal absorption, stability of formulation
US$ 29.70
US$ 22.86
US$ 26.75
US$ 26.14
US$ 24.96
